---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-001381"
form_type: "8-K"
ticker: "AMIX"
cik: "0001617867"
company_name: "Autonomix Medical, Inc."
filed_at: "2026-01-16T23:59:59+00:00"
generated_at: "2026-05-16T09:51:28.825054+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Autonomix Medical receives Nasdaq bid price deficiency notice; 180-day cure period

## Summary
- Received Nasdaq letter on Jan 14, 2026: bid price below $1.00 for 30 consecutive business days.
- Initial 180-day compliance period ends July 13, 2026; need $1.00 close for 10 consecutive days.
- If non-compliant by July 13, may get second 180-day period if meets other listing standards.
- Company may consider a reverse stock split to regain compliance with Bid Price Rule.
- No guarantee of regaining compliance; delisting possible if not cured or appeal fails.

## SEC filing metadata
- accession: 0001437749-26-001381
- form_type: 8-K
- ticker: AMIX
- cik: 0001617867
- company_name: Autonomix Medical, Inc.
- filed_at: 2026-01-16T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1617867/000143774926001381/0001437749-26-001381-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1617867/000143774926001381/amix20260114_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-001381
- JSON: https://secwatch.observer/filing/0001437749-26-001381.json
- Plain text: https://secwatch.observer/filing/0001437749-26-001381.txt

## Source-grounded claims
- claim_id: 4e3c94cd043816df74827b2c5cc1c81b676c0879
  claim: Autonomix Medical, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  evidence_excerpt: January 14, 2026, Autonomix Medical, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the closing bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The deficiency letter does not result in the immediate delisting of the Company’s common stock from the Nasdaq Capital
  evidence_url: https://www.sec.gov/Archives/edgar/data/1617867/000143774926001381/0001437749-26-001381-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.